By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
enGenes brings hi-tech biological production leadership to BioProcess International Vienna
Vienna, Austria: – High-yield end-to-end bioprocessing specialist CDMO enGenes Biotech will be present at the upcoming BioProcess International (BPI) European conference in Vienna in late April 2026.
enGenes Business Development Manager Ophelia Gevaert will represent enGenes at the conference to communicate the CDMO’s distinctive offers, technologies and capabilities in high end production of recombinant proteins, plasmid DNA, vaccines, antibodies, and peptides.
Proprietary platforms
Ms. Gevaert will also be able to show the benefits of proprietary enGenes technology platforms for advanced biomolecule production. These include:
- enGenes -eXpress™ as an optimized solution for the cost-effective production of recombinant protein and plasmid DNA in microbial expression systems
- enGenes -eXcess™ for enhanced yield decoupled recombinant proteins production in coli
- enGenes -eXchange™ for antibiotic-free and resistance marker-free manufacturing of recombinant proteins and high-quality plasmid DNA
- enGenes -eXrase™ next-generation recombinant endonuclease for powerful DNA/RNA digestion at a fraction of the cost of traditional market enzymes
- enGenes -eXcite™ as a cutting-edge technology that further supports continuous manufacturing of biomolecules in coli by enabling high yields and scalability from a very small footprint
Continuous bioprocessing breakthrough
Ophelia will also be able to point to the significant progress enGenes has made towards developing a truly continuous and enhanced sustainability biotech production process, thanks to learnings gained through its participation in the pioneering ECOnti project that combined advanced production methods with leveraged high end IT predictive control and conducting detailed economic modelling.
The project’s success also owed much to enGenes expertise in optimizing yields in end-to-end biomolecule manufacturing processes such as, in this instance, engineering a new strain of Escherichia coli optimized for continuous manufacturing.
Ophelia Gevaert will be available for consultations through the Informa ConnectMe app, as well as across the 12 hours of networking provided during the conference. She is accepting online bookings now for the event (see Resources).
About enGenes Biotech
With more than a decade of proven expertise, enGenes Biotech develops bioprocesses that consistently outperform conventional approaches. The company’s proprietary technology platforms deliver higher yields, faster timelines, and superior scalability for recombinant proteins, peptides and plasmid DNA production in E. coli. These directly translate into reduced production costs and accelerated market entry. From early concept to industrial process, they enable pharmaceutical, diagnostic and industrial applications to achieve results that set new industry benchmarks at a fraction of the cost.
enGenes Biotech’s expertise spans every step of the biomanufacturing lifecycle: molecular biology, upstream and downstream processing, analytics, process scale-up, product development, and market entry. It can deliver tailored solutions that reduce costs, advance sustainable innovation, and improve customers’ competitive position in the global marketplace.
The company offers development and manufacturing services for recombinant proteins, peptides, and plasmid DNA tailored to the needs of pharmaceutical and industrial biotech companies. Their integrated service portfolio ensures efficiency, quality, and speed in tackling even the toughest challenges. In addition, they are building a portfolio of high-quality and cost-effective products, with an initial focus on endonucleases and protein A-based affinity ligands.
Find out more at: https://www.engenes.cc
About BPI Europe 2026
BioProcess International Europe is becoming one of Europe’s leading bioprocessing conferences event for cutting-edge science, strategies, & digital tools to accelerate development of advanced biologics, including monoclonal antibodies (mAbs), ATMPs, and novel modalities.
The event attracts more than 800 researchers and professionals representing all phases of bioprocessing to hear more than 75 hours of scientific content from some 120 experts distributed across the four day event.
BPI Europe 2026 opens on April 27 at the Vienna Congress & Convention Center and will focus on the disruptive technologies that are transforming the adaptability, speed, and scalability of bioprocessing,
The event is organized by Informa Connect, with further information at: https://informaconnect.com/bpieurope/
Resources
Book a meeting with Ophelia Gevaert at BioProcess International Europe in Vienna.
Click on enGenes Biotech’s continuous microbial protein expression and purification to learn more.
Click on ECOnti – Accelerated, Low Ecological Footprint, Manufacturing to download factsheet on project.
Related Articles
